Press Releases

QIAGEN has announced the U.S. Food and Drug Administration approval of its therascreen KRAS RGQ PCR kit as a companion diagnostic test to Mirati Therapeutic’s drug KRAZATI for non-small cell lung cancer .QIAGEN and Mirati Therapeutics, Inc. a targeted oncology company, announced their cooperation in May 2021. The tissue based KRAS companion diagnostic assay, which QIAGEN developed specifically to identify patients with NSCLC that have a KRAS G12C mutation, is instrumental in determining

Lantern Pharma Inc. a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer  one of the most aggressive and malignant forms of breast cancer. New positive preclinical data on the anti-tumor potency of LP-184 for TN

Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable, authorized generics (AG) and complex generic medicines to enhance healthcare outcomes. Led by a team of industry veterans, Yaral Pharma will begin commercializing the first product from IBSA’s corporate pipeline of authorized generics in January 2023. Y

Agilent Technologies Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). This is the first liquid biopsy NGS assay approved by the FDA as a CDx for the newly approved KRAZATI in advanced NSCLC and was developed in collaboration with Mirati Ther

Tetris Pharma Ltd a subsidiary of biopharmaceutical company, Arecor Therapeutics plc  today announces that it has signed a service agreement with Syneos Health (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma’s commercial platform across Europe. Through this partnership, Syneos Health will provide commercial support through an outsourced contract sales

SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that its European partner Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Industries, has launched cenobamate in France. Cenobamate – under the brand name ONTOZRY – has been commercialized in five major European countries such as Germany, the UK, Italy, Spain, and France, accounting for about 73 percent of the total value of the continent'

Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of HALDOL (haloperidol) and HALDOL Decanoate (haloperidol decanoate) from Janssen Pharmaceutica NV. HALDOL is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced the creation of a dedicated center to enhance Emmes’ legacy and depth in cell and gene therapy research. The new center will focus on supporting the clinical trials of our clients who are developing cell and gene therapies around the world and across multiple therapeutic areas, including hematology, oncolo

The global pharma industry was out in full force at CPHI Frankfurt in November with 40,405 executives from 167 countries visiting the 2022 edition of the world-leading pharma industry tradeshow, a huge 75% increase over the number of attendees in 2021. Final visitor numbers will be confirmed by independent auditors ABC in early 2023. The increase in visitor numbers was all the more impressive because many visitors from China – who usually make up around 10% of the show’s

Delta-Fly Pharma, Inc. reports that the US Food and Drug Administration has received orphan drug designation for DFP-10917, a lead pipeline of the company of acute myeloid leukemia. With the ODD, Delta-Fly Pharma, Inc. could claim a seven-year market exclusivity and some benefits such as research and development credits in view of regulatory approval. DFP-10917 is an investigational anticancer compound for the treatment of patients with refractory/relapsed AML. A Phase 3 c